Literature DB >> 8297651

Cytokine gene expression in primary brain tumours, metastases and meningiomas suggests specific transcription patterns.

A Merlo1, A Juretic, M Zuber, L Filgueira, U Lüscher, V Caetano, J Ulrich, O Gratzl, M Heberer, G C Spagnoli.   

Abstract

To obtain an insight into the network of cytokine gene transcription in the brain tumour microenvironment, we investigated the expression of genes encoding for interleukin (IL)-1 alpha, IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-10, interferon (IFN)-gamma, granulocyte-macrophage colony-stimulating factor, tumour necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta 1, -beta 2 and -beta 3 in freshly excised brain tumour samples and autologous peripheral blood mononuclear cells. Tissue specimens from 15 primary brain tumours, three brain metastases, five meningiomas, autologous peripheral blood mononuclear cells (PBMC) and three brain tumour cell lines were tested by reverse polymerase chain reaction. Despite the presence of T-lymphocytes, cytokine gene transcripts typically detectable upon T cell receptor triggering could not be observed in central nervous system tumours of diverse histology. In primary brain neoplasms, transcription of genes encoding for the inhibitory cytokines TGF-beta and IL-10 was detectable in more than 50% of samples. IL-6 transcripts could only be detected in malignant gliomas. In brain metastases, virtually no cytokine gene transcripts could be observed. Surprisingly, TGF-beta transcripts were also detected in all meningiomas. Thus, transcription of genes encoding for inhibitory factors appears to prevail in primary brain neoplasms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8297651     DOI: 10.1016/0959-8049(93)90046-i

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 2.  Cytokines in tumour growth, migration and metastasis.

Authors:  R P Negus; F R Balkwill
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

3.  Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas.

Authors:  Christopher L Mariani; Didier Rajon; Francis J Bova; Wolfgang J Streit
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

4.  Immune infiltrates and cytokines in gliomas.

Authors:  B Giometto; F Bozza; F Faresin; L Alessio; S Mingrino; B Tavolato
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

5.  Transforming growth factor-beta effects on meningioma cell proliferation and signal transduction pathways.

Authors:  Mahlon D Johnson; Evelyn Okediji; Ann Woodard
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

6.  The treatment of malignant meningioma with verotoxin.

Authors:  Bodour Salhia; James T Rutka; Clifford Lingwood; Anita Nutikka; Wouter R Van Furth
Journal:  Neoplasia       Date:  2002 Jul-Aug       Impact factor: 5.715

7.  High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours.

Authors:  E Venetsanakos; I Beckman; J Bradley; J M Skinner
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 8.  The Process and Regulatory Components of Inflammation in Brain Oncogenesis.

Authors:  A G M Mostofa; Surendra R Punganuru; Hanumantha Rao Madala; Mohammad Al-Obaide; Kalkunte S Srivenugopal
Journal:  Biomolecules       Date:  2017-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.